[Skip to Content]
[Skip to Content Landing]
Views 329
Citations 0
News From the Food and Drug Administration
July 18, 2017

Generic ADHD Drug

JAMA. 2017;318(3):232. doi:10.1001/jama.2017.8439

The first generic versions of atomoxetine used for treating attention-deficit/hyperactivity disorder (ADHD) in children and adults have been approved.

A selective norepinephrine reuptake inhibitor, atomoxetine received FDA approval in 2002. Eli Lilly and Company of Indianapolis, Indiana, has marketed the drug as Strattera. Generic versions in various dosages will be manufactured by Apotex Inc of Toronto, Ontario, Canada; Teva Pharmaceuticals USA Inc of North Wales, Pennsylvania; Aurobindo Pharma Limited of Hyderabad, India; and Glenmark Pharmaceuticals Limited of Mumbai, India.

First Page Preview View Large
First page PDF preview
First page PDF preview
×